Susan Storey1, Tamryn Fowler Gray2, Ashley Leak Bryant3. 1. Indiana University School of Nursing, Indianapolis, IN 46202. 2. Johns Hopkins University, School of Nursing. 3. School of Nursing, The University of North Carolina at Chapel Hill, 401 Carrington Hall, #7460, Chapel Hill, NC 27599, Office: 919-966-5628.
Abstract
PURPOSE OF REVIEW: To describe the pathology, impact of comorbidities, functional limitations, symptoms, and quality of life (QOL) related to treatment of acute myeloid leukemia (AML) in older adults. RECENT FINDINGS: AML is a rare aggressive hematologic disease that occurs most often in older adults. The prognosis for older patients with AML is markedly worse due to genetic mutations and patient characteristics such as comorbidities and functional limitations. Patient characteristics may influence treatment decisions, as well as impact symptoms, functional ability, health-related outcomes and (QOL). SUMMARY: As the population continues to age, the number of people diagnosed with AML is expected to increase. Better management of comorbidities is imperative to improving QOL and other treatment related outcomes. Prospective, longitudinal and multi-site studies are warranted to further understand the interaction between these characteristics on symptoms, outcomes and QOL.
PURPOSE OF REVIEW: To describe the pathology, impact of comorbidities, functional limitations, symptoms, and quality of life (QOL) related to treatment of acute myeloid leukemia (AML) in older adults. RECENT FINDINGS: AML is a rare aggressive hematologic disease that occurs most often in older adults. The prognosis for older patients with AML is markedly worse due to genetic mutations and patient characteristics such as comorbidities and functional limitations. Patient characteristics may influence treatment decisions, as well as impact symptoms, functional ability, health-related outcomes and (QOL). SUMMARY: As the population continues to age, the number of people diagnosed with AML is expected to increase. Better management of comorbidities is imperative to improving QOL and other treatment related outcomes. Prospective, longitudinal and multi-site studies are warranted to further understand the interaction between these characteristics on symptoms, outcomes and QOL.
Authors: Edward Giovannucci; David M Harlan; Michael C Archer; Richard M Bergenstal; Susan M Gapstur; Laurel A Habel; Michael Pollak; Judith G Regensteiner; Douglas Yee Journal: CA Cancer J Clin Date: 2010-06-16 Impact factor: 508.702
Authors: Kenneth H Chuang; Kenneth E Covinsky; Laura P Sands; Richard H Fortinsky; Robert M Palmer; C Seth Landefeld Journal: J Am Geriatr Soc Date: 2003-12 Impact factor: 5.562
Authors: Bernard Tawfik; Timothy S Pardee; Scott Isom; Sarunas Sliesoraitis; Allison Winter; Julia Lawrence; Bayard L Powell; Heidi D Klepin Journal: J Geriatr Oncol Date: 2015-10-30 Impact factor: 3.599
Authors: Pauline A J Vissers; Louise Falzon; Lonneke V van de Poll-Franse; Frans Pouwer; Melissa S Y Thong Journal: J Cancer Surviv Date: 2015-10-01 Impact factor: 4.442
Authors: Mary Jarden; Tom Møller; Lars Kjeldsen; Henrik Birgens; Jesper Frank Christensen; Karl Bang Christensen; Finn Diderichsen; Carsten Hendriksen; Lis Adamsen Journal: BMC Cancer Date: 2013-10-02 Impact factor: 4.430
Authors: María García-Fortes; Juan C Hernández-Boluda; Alberto Álvarez-Larrán; José M Raya; Anna Angona; Natalia Estrada; Laura Fox; Beatriz Cuevas; María C García-Hernández; María Teresa Gómez-Casares; Francisca Ferrer-Marín; Silvana Saavedra; Francisco Cervantes; Regina García-Delgado Journal: Cancers (Basel) Date: 2022-05-09 Impact factor: 6.575
Authors: Keith W Pratz; Panayiotis Panayiotidis; Christian Recher; Xudong Wei; Brian A Jonas; Pau Montesinos; Vladimir Ivanov; Andre C Schuh; Courtney D DiNardo; Jan Novak; Vlatko Pejsa; Don Stevens; Su-Peng Yeh; Inho Kim; Mehmet Turgut; Nicola Fracchiolla; Kazuhito Yamamoto; Yishai Ofran; Andrew H Wei; Cat N Bui; Katy Benjamin; Rajesh Kamalakar; Jalaja Potluri; Wellington Mendes; Jacob Devine; Walter Fiedler Journal: Blood Cancer J Date: 2022-04-20 Impact factor: 9.812